Aadi Bioscience Charts a New Course with Strategic Pivot

Shares of Aadi Bioscience have demonstrated stability as the biotechnology firm executes a fundamental strategic overhaul. The company is shifting its focus from a marketed drug to building a preclinical pipeline centered on antibody-drug conjugates (ADCs). This redirection was facilitated by a series of financial maneuvers designed to secure the company’s liquidity well into the latter half of this decade.

The corporate transformation is built upon three pivotal actions, fundamentally altering Aadi’s business model:

1. Divestment of Commercial Asset: Aadi sold its commercialized drug, FYARRO®, to Kaken Pharmaceuticals for $100 million in cash.
2. Pipeline Acquisition: Concurrently, the company in-licensed an exclusive portfolio of Read more...